Innovation at Boehringer Ingelheim is inscribed in our Company’s vision: **Value Through Innovation**. Yet to continuously innovate requires a commitment to explore further and work harder to remain at the forefront of science and technology and achieve our ambition of discovering and developing new medicines that improve patients’ lives and create value for all our customers.

### Accelerating Innovation

As a global pharmaceutical company, the discovery and development of innovative medicines is the prerequisite for our growth and success. This means achieving our ambition of developing a portfolio of **first-in-class treatments** and therapies with **breakthrough potential**. Our **blueprint for innovation** has been tailored to **accelerate the delivery** of new and advanced medicines to the patients we serve by integrating research, pre-clinical and early clinical development and external partnering functions. This **fusion of expertise** combined with a **progressive innovation strategy** and an increased emphasis on **external collaborations** allows us to **incubate the most creative ideas** and be among the pioneers in emerging fields of medicine.

This vision is supported by **industry-leading levels of investment** totaling 11 billion euro. This includes 5 billion euro for pre-clinical R&D of which around one-third is designated for collaborations with external partners.*


### A Progressive Innovation Strategy

Our innovation strategy positions us for the future of healthcare in three ways:

1. **Building on our strengths** by focusing on the discovery and development of novel therapies for patients in our therapeutic areas of focus
2. **Creating synergies** by identifying and exploring unifying scientific platforms and enabling technologies with the potential to impact across our therapeutic areas
3. **Harnessing emerging science and technology** within and beyond our therapeutic areas to develop treatments that create new reference points.

Together with our broad community of innovation partners, we are incubating the most creative ideas and pioneering emerging fields of research so we can continuously deliver meaningful innovations that improve patients’ lives.

### Global Research and Development Presence

Our highly-skilled team in research, development and medicine works in key locations in Europe, North America and Asia. Leveraging our **advanced R&D capabilities**, we are working together with our expanding global network of academic and industry partners to practice **cutting-edge science** with focused risk-taking to develop treatments that create new reference points.

**MORE INFORMATION**

For more information please visit: partnering.boehringer-ingelheim.com
For partnering contacts please visit: boehringer-ingelheim.com/partnering/news/contacts
For Venture Fund information please visit: boehringer-ingelheim-venture.com
For media enquiries please contact Dr. Reinhard Malin: reinhard.malin@boehringer-ingelheim.com; phone: +49 6132 77 90815
Growing our Global Community of Innovation Partners

External collaborations play an essential role in helping us fully address the healthcare challenges of the future. With our increased investment in R&D, we are increasing our emphasis on external collaborations and expanding our global network of innovation partners – informed by science and supported through a broad range of partnering and investment models. This is supplemented by our ongoing Corporate Venture Fund activities which continue to drive innovation through strategic investments in early-stage science and technology.

Insights from our broad community of dedicated scientists around the world inspire us and are key to our team’s enthusiasm for shared scientific discovery. Our long tradition of successful partnerships has resulted in around 50% of our early-mid stage pipeline anchored in external collaborations.

Innovating from Science to Sales

Our record of breakthrough innovations in recent years is evidence of the capabilities of our highly effective global R&D engine that is also driving the next generation of medicines through our pipeline. But while science is the starting point, facilitating success for a project requires a multidisciplinary approach. Transitioning the science from the laboratory to the hands of clinicians involves teams of highly qualified professionals with a broad range of expertise. From the scientists in our research centers to our sales professionals around the world, our global teams provide industry-leading skills to complement our partners’ expertise.

Experience our Difference

Long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an authentic team environment, resulting in the potential for faster and better results. These values, together with our success and our passion for science, encourage us each day to explore further and work harder to discover and develop new medicines for the many diseases for which there are still no effective treatments. This is made possible through our long-term research and investment focus that enables us to fully commit to enduring partnerships and provide sustained investment for tomorrow’s medical breakthroughs.

With an outstanding team, a track record of scientific excellence, patients who motivate us and partners who inspire us, our ‘innovation equation’ uniquely positions us to meet the scientific challenges we face with conviction.

MORE INFORMATION

For more information please visit: partnering.boehringer-ingelheim.com
For partnering contacts please visit: boehringer-ingelheim.com/partnering/news/contacts
For Venture Fund information please visit: boehringer-ingelheim-venture.com
For media enquiries please contact Dr. Reinhard Malin: reinhard.malin@boehringer-ingelheim.com; phone: +49 6132 77 90815